Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -91.83M | -101.20M | -104.32M | -101.85M | -28.84M |
| Total Depreciation and Amortization | 556.40K | 504.10K | 375.00K | 255.60K | 143.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 65.00M | 67.34M | 70.25M | 71.92M | 13.19M |
| Change in Net Operating Assets | 14.19M | 6.85M | 4.33M | 1.49M | -2.04M |
| Cash from Operations | -12.09M | -26.51M | -29.36M | -28.19M | -17.55M |
| Capital Expenditure | -103.40K | -166.70K | -184.80K | -183.00K | -89.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 13.11M | 13.65M | 13.65M | 13.65M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -103.40K | 12.94M | 13.46M | 13.46M | 13.56M |
| Total Debt Issued | 500.00K | 500.00K | 14.87M | 14.87M | 14.77M |
| Total Debt Repaid | -10.10M | -10.20M | -10.20M | -897.70K | -97.70K |
| Issuance of Common Stock | 8.11M | 13.85M | 13.80M | 7.34M | 6.45M |
| Repurchase of Common Stock | -102.60K | -102.60K | -51.30K | -- | -4.50M |
| Issuance of Preferred Stock | -- | -- | 3.53M | 5.69M | 7.34M |
| Repurchase of Preferred Stock | -- | -5.69M | -5.69M | -5.69M | -5.69M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -329.40K | -329.30K | -390.90K |
| Cash from Financing | -1.60M | -1.64M | 15.93M | 20.99M | 17.89M |
| Foreign Exchange rate Adjustments | 81.30K | 37.10K | -32.80K | -6.70K | -2.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.71M | -15.17M | 300.00 | 6.25M | 13.90M |